Approved Vimovo for arthritis patients at risk of NSAID-associated gastric Pozen Inc.

And the the U.S. Food and Drug Administration with Vimovo delayed-release tablets approved the relief from signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk for developing NSAID-associated gastric ulcers. of Vimovo Pozen Inc. Co – developed and AstraZeneca, is a fixed-dose combination of enteric-coated naproxen, a pain-relieving non-steroidal anti – inflammatory drug , and immediate-release esomeprazole, a proton pump inhibitor .

About VimovoVimovo is a fixed dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug , and immediate-release esomeprazole, a stomach acid-reducing proton pump inhibitor , for reducing the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and the risk of developing gastric ulcers in patients at risk for developing NSAID-associated gastric ulcers reduce approved. Vimovo is not recommended for use in children younger than 18 years .Be horizontal application by the state Department of Banking and Insurance, which is required to be verified public events of public meetings on the map MarinoSaudi said that. He hopes a decision also be in the first half of 2009 to pass.

Other Posts From "obstetrics":

Related Posts